利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.018 秒)

    NEISSERIAL VACCINES
    4.
    发明公开
    NEISSERIAL VACCINES 审中-公开
    奈瑟-IMPFSTOFF

    公开(公告)号：EP2481419A2

    公开(公告)日：2012-08-01

    申请号：EP12157807.4

    申请日：2003-07-31

    申请人： GlaxoSmithKline Biologicals S.A.

    发明人： Biemans, Ralph ,  Denoel, Philippe ,  Feron, Christiane ,  Goraj, Carine ,  Poolman, Jan ,  Weynants, Vincent

    IPC分类号： A61K39/095 ,  A61P31/04

    CPC分类号： A61K39/095 ,  A61K39/102 ,  A61K39/1045 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/22 ,  Y02A50/396

    摘要： The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA & OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. The FrpB downregulation is also described. Alternatively, or in addition, IgtB - is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from IgtB - and capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

    摘要翻译： 本发明涉及奈瑟氏球菌疫苗组合物的领域，它们的制造以及这些组合物在医药中的应用。 更具体地说，涉及制备新型工程化脑膜炎球菌菌株的方法，这些菌株更适合于产生奈司菌素，特别是脑膜炎球菌，外膜囊泡（或气泡）疫苗。 还基于使用已经变得更安全和/或更有效地用于人类受试者的新型LOS亚单位或脑膜炎球菌外膜囊泡（或泡沫）疫苗来描述有利的方法和疫苗产品。 描述了基因下调的组合，例如PorA和OpA，PorA和OpC，OpA和OpC，以及PorA和OpA和OpC。 还描述了FrpB下调。 或者或另外，IgtB-被证明是在奈瑟氏球菌疫苗组合物中有效和安全地使用L3和/或L2 LOS的最佳突变。 衍生自IgtB-和荚膜多糖缺乏型脑膜炎球菌突变体的Bleb疫苗进一步描述; 制备其中保留LOS作为重要抗原的泡制剂的有利方法也是如此。